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SCARF-1 promotes adhesion of 
CD4+ T cells to human hepatic 
sinusoidal endothelium under 
conditions of shear stress
Daniel A. Patten  , Sivesh K. Kamarajah, Joanne M. Rose, Joseph Tickle, Emma L. Shepherd, 
David H. Adams, Chris J. Weston  & Shishir Shetty
Liver-resident cells are constantly exposed to gut-derived antigens via portal blood and, as a 
consequence, they express a unique repertoire of scavenger receptors. Whilst there is increasing 
evidence that the gut contributes to chronic inflammatory liver disease, the role of scavenger 
receptors in regulating liver inflammation remains limited. Here, we describe for the first time the 
expression of scavenger receptor class F, member 1 (SCARF-1) on hepatic sinusoidal endothelial 
cells (HSEC). We report that SCARF-1 shows a highly localised expression pattern and co-localised 
with endothelial markers on sinusoidal endothelium. Analysis of chronically inflamed liver tissue 
demonstrated accumulation of SCARF-1 at sites of CD4+ T cell aggregation. We then studied the 
regulation and functional role of SCARF-1 in HSEC and showed that SCARF-1 expression by HSEC is 
regulated by proinflammatory cytokines and bacterial lipopolysaccharide (LPS). Furthermore, SCARF-1 
expression by HSEC, induced by proinflammatory and gut-derived factors acts as a novel adhesion 
molecule, present in adhesive cup structures, that specifically supports CD4+ T cells under conditions 
of physiological shear stress. In conclusion, we show that SCARF-1 contributes to lymphocyte subset 
adhesion to primary human HSEC and could play an important role in regulating the inflammatory 
response during chronic liver disease.
The liver receives 75–80% of its blood supply from the gut and consequently the cells of the liver are exposed to 
a vast array of microbial antigens. In order to cope with this constant antigenic load, liver cells express a range 
of professional pattern recognition receptors, that allow them to discriminate between harmless and damaging 
antigens1. There is now increasing evidence to implicate these gut-derived, microbial-associated molecular pat-
terns (MAMPs) in contributing to a range of liver diseases including non-alcoholic fatty liver disease (NAFLD), 
alcoholic liver disease (ALD) and autoimmune liver diseases, such as primary biliary cholangitis (PBC) and pri-
mary sclerosing cholangitis (PSC)2. Thus far, research has focused on TLRs as key players in the innate immune 
response to MAMPs3 but other classes of pattern recognition receptors are also likely to play an important role.
Scavenger receptors are a large superfamily of proteins first identified by their ability to bind and subsequently 
internalise oxidised low density lipoproteins (oxLDLs)4. They are now known to bind multiple endogenous and 
exogenous products5, including a wide array of microbial antigens6. Functionally, scavenger receptors play impor-
tant roles in the maintenance of tissue homeostasis and protection from infection but they may also be implicated 
in the persistence of injury in inflammatory disorders including chronic liver diseases5,7. Scavenger receptors 
expressed by hepatocytes and resident macrophages (Kupffer cells) have been implicated in the pathogenesis of 
viral hepatitis8,9, metabolic-induced liver injury10,11 and fibrosis12,13. Hepatic sinusoidal endothelial cells (HSEC), 
which represent the second most abundant cell type in the human liver, express an array of scavenger receptors 
at high density consistent with their role in removing microbial antigens from the portal blood. We have also 
reported that they play an important role in leukocyte recruitment to the liver. Previous work has shown that 
the scavenger receptor, Stabilin-1, is expressed by HSEC in a range of chronic liver diseases and hepatocellular 
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carcinoma14,15 where it is involved in the recruitment of regulatory T (Treg) lymphocytes and B cells to the liver15,16. 
Additionally, the Stabilin-1 homologue, Stabilin-217, CD3618 and scavenger receptor BI19 have also been reported 
to be expressed in HSEC.
Scavenger receptor class F, member 1 (SCARF-1), also known as scavenger receptor expressed by endothelial 
cells (SREC)-I is expressed in murine liver sinusoidal endothelial cells20; however, its cell-specific expression and 
function in the human liver is unknown. SCARF-1 is an evolutionarily conserved scavenger receptor21, first iden-
tified in cDNA libraries from human umbilical vein endothelial cells (HUVEC)22. SCARF-1 has been shown to 
bind modified low density lipoproteins (LDLs), specifically acetylated-LDLs (acLDLs)23, and acts as an endocytic 
receptor for a wide range of damage-associated products including heat-shock proteins (Hsps)24–26 and apoptotic 
host cells via the C1q protein27. In addition to binding and internalising a diverse range of endogenous proteins, 
SCARF-1 also binds a wide array of viral20,28,29, fungal21 and bacterial30–33 antigens. SCARF-2, also known as 
SREC-II, shows a 35% homology to SCARF-1 and exhibits a similar transcriptional expression pattern across a 
range of human tissues34; however, less is known about the scavenging function of SCARF-2, with SCARF-1 being 
its only known ligand34.
In this study, we describe SCARF-1 expression in the sinusoids and major vessels of the normal human liver 
and within fibrotic septa of chronic liver diseases and the peritumoral stroma of hepatocellular carcinoma (HCC). 
In view of the sinusoidal and vascular pattern of SCARF-1 expression we hypothesised that it may have a role in 
leukocyte recruitment. Initially, we detected SCARF-1 expression in isolated HSEC and showed its up-regulation 
in vitro by proinflammatory cytokines, bacterial LPS and tumourigenic growth factors. Functionally, we demon-
strate that immobilised recombinant human (rh)SCARF-1 can directly interact with CD4+ T lymphocytes in 
the presence of vascular cell adhesion molecule (VCAM)-1 in vitro, and can support CD4+ T cell adhesion to 
HSEC stimulated with TNFα and LPS, under conditions of physiological flow through a SCARF-1 rich adhesive 
cup-like structure containing adherent CD4+ T cells.
Results
SCARF-1 in normal liver, chronic liver disease and malignancy. Immunohistochemistry of normal 
human liver tissue demonstrated localised expression of SCARF-1 within the sinusoids and on the major vascu-
lature of the liver; this was also the case in a range of chronic liver diseases where we noted increased presence 
of SCARF-1 on vessels and fibrotic septa in chronic inflammatory liver disease (Fig. 1a). Western blot analysis 
detected a protein of 90 kDa (SCARF-1 predicted size 87.4 kDa) and a dimer species 180 kDa in size that were 
present in both normal and diseased tissue, in addition to a 60 kDa species present in diseased tissue, which was 
absent from normal liver tissue (Fig. 1b). Many scavenger receptors are regulated via cell surface cleavage by exo-
facial proteases resulting in release of a soluble form of the scavenger receptor into the circulation5. We confirmed 
the presence of a soluble form of SCARF-1 (sSCARF-1) in human serum, with values ranging from 1–20 ng/ml in 
the cohort of samples tested (Fig. 1c) and show via Western blot that the predominant immunoreactive SCARF-1 
species in serum is the 60 kDa form (Fig. 1d). However, despite significantly increased expression of the proposed 
60 kDa form of SCARF-1 within chronically diseased liver tissue sections (Fig. 1a), there were no significant dif-
ferences in sSCARF-1 concentrations in serum from patients with chronic liver disease (PSC and PBC) compared 
to healthy donor controls (Fig. 1c). In contrast to this, increased expression of SCARF-1 mRNA was present in 
chronic liver disease samples (Fig. 1e).
Patients with chronic liver disease are susceptible to developing hepatocellular carcinoma (HCC) on the 
background of cirrhosis. Having observed elevated levels of SCARF-1 in end-stage liver disease, we inves-
tigated whether SCARF-1 was also expressed in the tumour environment. We detected SCARF-1 in HCC at 
different stages of differentiation in which the protein and was mainly associated with tumour sinusoids and 
tumour-associated vessels (Supplementary Figure 1a) and within the tumour margin and on capsule-associated 
vessels (Supplementary Figure 1b). Staining in poorly differentiated HCC tumour was greatly reduced compared 
with well- and moderately-differentiated tumours. SCARF-1 mRNA levels in HCC tumour tissue also demon-
strated a trend for down-regulation, compared to normal liver tissue (Supplementary Figure 1c).
Given the differential expression of SCARF-1 in normal and diseased livers, we also studied the expression 
pattern of a close homologue, SCARF-2. Immunohistochemical staining of normal liver demonstrated diffuse 
cytoplasmic expression of SCARF-2 throughout the parenchymal tissue (Supplementary Figure 2a). In contrast 
to SCARF-1, SCARF-2 did not appear to be upregulated in disease state, as a similarly diffuse, yet more heter-
ogeneous, cytoplasmic staining pattern was observed in the parenchymal tissue of chronically diseased livers 
(Supplementary Figure 2a). Expression levels of immunoreactive protein of ~100 kDa in size (predicted molec-
ular weight of SCARF-2, 92 kDa) were similar between normal and diseased tissue (Supplementary Figure 2b). 
However, consistent with with observations for SCARF-1, we also detected a lower molecular weight species 
(55 kDa) which was present in diseased tissue, and undetectable in normal liver tissue lysates (Supplementary 
Figure 2b). This was associated with an upregulation in SCARF-2 mRNA expression (Supplementary Figure 2c).
HSEC express SCARF-1 in vivo and in vitro. Given the differences in expression and distribution of 
SCARF-1 in chronic liver disease we proceeded to study its cell-specific expression in liver tissue. Dual immu-
nofluorescence staining of CD31 and SCARF-1 within diseased liver tissue demonstrated strong co-localisation 
within hepatic sinusoidal and vascular endothelium in the liver (Fig. 2a; top left panel). Also, co-localisation of 
SCARF-1 with α-smooth muscle actin (α-SMA) and CD90, markers of activated stellate cells and fibroblasts, 
respectively, was seen at the interface between the fibrotic septum and parenchymal tissue in chronic liver disease 
(Fig. 2a; top middle panel and top right panel). Only a subset of CD68+ cells (macrophages) appeared to co-express 
SCARF-1 (Fig. 2a; bottom left panel). Hepatocytes (CK18; Fig. 2a; bottom middle panel) and biliary epithelial cells 
(BEC; EpCAM; Fig. 2a; bottom right panel) were negative for SCARF-1 expression.
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We next isolated the liver cell types that stained for SCARF-1 in tissue, namely HSEC, hepatic stellate cells 
(HSCs) and activated liver myofibroblasts (aLMFs). We detected SCARF-1 mRNA in all the cell types but gene 
expression of SCARF-1 was significantly (300–400-fold) higher in HSEC compared to both HSCs and aLMFs 
(Fig. 2b). Interestingly, HSEC transcriptional expression of SCARF-1 was also double that of cells from a more 
conventional endothelium, human umbilical vein endothelial cells (HUVEC; Supplementary Figure 3); the cells 
in which SCARF-1 was first described22.
Our previous work has demonstrated that other scavenger receptors expressed by hepatic endothelial cells, 
such as stabilin-1, can drive lymphocyte recruitment in chronic liver disease, with particular specificity for reg-
ulatory T cells and B cells15,16. Consequently, immunofluorescence of liver tissue confirmed that SCARF-1 was 
prevalent around areas of CD4+ T cell infiltration in diseased livers (Fig. 2c,d).
Regulation of SCARF-1 in HSEC. We next studied protein expression of SCARF-1 in isolated HSEC, via 
immunofluorescent staining and found a vesicular and perinuclear distribution of SCARF-1 (Fig. 3a; far left 
panel), which was similar to the intracellular distribution of our previous studies on stabilin-115. Having detected 
increased SCARF-1 expression in sites of chronic inflammation, we sought to regulate its expression in HSEC 
with proinflammatory cytokines. TNFα alone and in combination with IFNγ led to an upregulation of SCARF-1 
protein as measured by immunofluorescence and cell based ELISA (Fig. 3a; middle panels; Fig. 3c). Additionally, 
we explored the regulatory effects of bacterial lipopolysaccharide (LPS), a known ligand for SCARF-133 and a 
key factor in many chronic liver diseases35 and hepatic malignancies36. Incubation of HSEC with LPS led to an 
increase in SCARF-1 expression, in a similar manner to that observed for cytokine stimulation (Fig. 3a; far right 
Figure 1. SCARF-1 expression is up-regulated in chronic liver disease. (a) Immunohistochemical staining of 
SCARF-1 (brown) in representative images of normal liver (NL), primary sclerosing cholangitis (PSC), primary 
biliary cholangitis (PBC), alcoholic liver disease (ALD) and non-alcoholic steatohepatitis (NASH). Insets show 
a higher magnification of the parenchymal tissues. Fibrotic septa are delineated by the dashed black lines. 
Scale bar = 200 µm. Inset scale bar = 50 µm. Surface area quantification of immunohistochemical staining. 
****Represents statistical significance where p ≤ 0.001. n = 4–8 in each group (bottom right panel). (b) Western 
blot (left panel) and quantification (right panels) of the ~180 kDa, ~90 kDa and ~60 kDa species of SCARF-1  
in normal liver (NL) and chronic liver disease (CLD). **Represents statistical significance where p ≤ 0.01. 
n = 4–8 in each group. Results are regions cropped from the same membrane (see Supplementary Figure 7).  
(c) Sandwich ELISA analysis of soluble SCARF-1 (sSCARF-1) in human serum. n = 5–10 in each group.  
(d) Western blot of SCARF-1 in serum from 3 individual PSC patients. Black arrow indicates the major species 
at ~60 kDa. Results cropped from the same membrane (see Supplementary Figure 7). (e) SCARF-1 mRNA 
expression in normal liver (NL) and chronic liver disease (CLD) tissue. ***Represents p ≤ 0.005. n = 8 in NL 
and n = 26 in CLD group.
www.nature.com/scientificreports/
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Figure 2. HSEC represent a major cell type expressing SCARF-1 in CLD. (a) Representative images of dual 
colour immunofluorescent staining on chronically diseased (ALD and PSC) liver for SCARF-1 (green) and 
endothelial marker CD31 (top left panel), activated stellate cell marker α-SMA (smooth muscle actin; top middle 
panel), fibroblast marker CD90 (top right panel), macrophage marker CD68 (bottom left panel), hepatocyte 
marker CK18 (bottom middle panel) and biliary epithelial marker EpCAM (bottom right panel). Insets show 
magnification of SCARF-1 and cell-specific markers. Scale bar = 50 µm. Inset scale bar = 10 µm. (b) SCARF-1 
mRNA expression in isolated human hepatic sinusoidal endothelial cells (HSECs), hepatic stellate cells (HSCs) 
and activated liver myofibroblasts (aLMFs). ****Indicates statistical significance where p ≤ 0.001. n = 5–10 in 
each group. (c) Representative images of dual colour immunofluorescent staining of SCARF-1 (green) and CD4 
(red) in normal liver (NL) and chronically diseased livers (PSC and PBC). Scale bar = 250 µm. White dashed 
lines delineate sites of intensity measurements. (b) Intensity measurements of immunofluorescent staining 
shown in (a). Black arrows indicate areas of stronf co-localisation of SCARF-1 (green) and CD4 (red).
www.nature.com/scientificreports/
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panel; Fig. 3c). To confirm these findings we also performed western blotting analysis for protein quantifica-
tion. We found that in cultured HSEC, SCARF-1 was present in both monomeric and dimeric forms. Increased 
expression of the dimer was only observed following stimulation with both TNFα and IFNγ whereas increased 
expression of the monomer was observed following LPS stimulation (Fig. 3b). This effect was largely independent 
of transcription of SCARF-1 (Fig. 3d). We were unable to detect a 60 kDa immunoreactive species in these cell 
lysates, possibly reflecting the absence of the myriad proteinases present in chronic liver disease.
Given the high sinusoidal expression of SCARF-1 in HCC tumour, we also investigated the effects of the 
tumourigenic growth factors, hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) 
and found that they also increased the cellular expression of SCARF-1 in HSEC, as determined by cell-based 
ELISA (Supplementary Figure 4a), without increasing transcription (Supplementary Figure 4b). Further analysis 
of protein expression by Western blotting, once again detected both monomer and dimer forms of SCARF-1 
which were relatively unchanged following growth factor stimulation (Supplementary Figure 4c).
Recombinant SCARF-1 mediates CD4+ T cell adhesion. Given the similarities in expression of 
SCARF-1 and stabilin-1, and the fact that both scavenger receptors contain a number of EGF-like moieties in 
their extracellular domains, we hypothesised that, like stabilin-1, SCARF-1 might function as an atypical adhesion 
molecule. To test this, we used a flow-based adhesion assay with immobilised recombinant human (rh)SCARF-1 
to study interactions of the Jurkat leukaemic T cell line and primary CD4+ and CD8+ T cells. In order to maintain 
the correct orientation of the protein in the assay we immobilised a commercially available rhSCARF-1 Fc chi-
mera to plate bound protein G (Fig. 4a). Immobilised rhSCARF-1 alone was unable to support lymphocyte adhe-
sion (data not shown) and because endothelial molecules operate in combinatorial systems we co-immobilised 
VCAM-1 (which is known to mediate rolling of leukocytes on endothelium37) with SCARF-1 and found that the 
presence of rhSCARF-1 significantly augments the adhesion of Jurkat and CD4+ T cells to VCAM-1 under flow 
Figure 3. In vitro expression of SCARF-1 in HSEC can be up-regulated by proinflammatory cytokines and 
LPS. (a) Representative images of immunofluorescent staining of SCARF-1 (green) with DAPI nuclear stain 
(blue). Scale bar = 25 µm. (b) Representative Western blot (left panel) and quantification (right panels) of the 
180 kDa (dimeric) and 90 kDa (monomeric) species of SCARF-1 in stimulated HSEC compared to media alone 
control (Con). Results are representative of 3 independent experiments and are regions cropped from the same 
membrane (see Supplementary Figure 7). (c) Fold change in SCARF-1 protein expression measured by cell-
based ELISA in stimulated HSEC. (d) qPCR analysis of SCARF-1 mRNA in stimulated HSEC. (a–d) HSEC were 
treated with 10 ng/ml of tumour necrosis factor (TNF)α, 10 ng/ml of interferon (IFN)γ, or both in combination 
or with 1 µg/ml of LPS for 24 h. (c and d) Dotted lines indicate control level of expression. * and ** indicate 
statistical significance where p ≤ 0.05 and p ≤ 0.01, respectively. (b and d) n = 3 and (c) n = 5 independent 
experiments with different HSEC donors in each group.
www.nature.com/scientificreports/
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conditions (Supplementary Figure 5a and Fig. 4b). Conversely, no effect on CD8+ T cell adhesion was detected 
(Fig. 4c). To confirm that this additional adhesion was a consequence of binding to SCARF-1 and not due to 
altered stoichiometry of the two immobilised proteins, we were able to reverse the SCARF-1-mediated augmen-
tation of CD4+ T cell adhesion with anti-SCARF-1 antibody blockade (Supplementary Figure 5b; Fig. 4d); it 
should be noted that addition of the SCARF-1 blocking antibody had no effect on CD8+ adhesion, thus ruling out 
non-specific steric interference of antibody binding on T-cell adhesion to VCAM-1 (Fig. 4e). It is also important 
to note that, in this system, the addition of recombinant protein G alone had no effect on the binding ability of 
immobilised rhVCAM-1 (data not shown).
SCARF-1 acts as an adhesion molecule on stimulated HSEC. To understand the relevance of this to 
HSEC biology we used confocal microscopy to visualise the direct interaction between HSEC-expressed SCARF-1 
and CD4+ T cells under flow conditions. We found that, where CD4+ T cells adhered to HSEC, ring-like clus-
ters of SCARF-1 were evident (Fig. 5a and b; left panel). It is important to note that CD4+ T cells do not express 
SCARF-1 mRNA (data not shown) and the SCARF-1 expression pattern observed is thus most likely associated 
with the endothelial cells and not the lymphocytes themselves. Z-stack imaging confirmed this ring-like enrich-
ment of SCARF-1 present on the HSEC and showed SCARF-1+ structures which appear to extend out from the 
cell surface, thus stabilising the CD4+ T cell on the endothelium (Fig. 5b; right panel). These structures resembled 
endothelial docking structures described in previous studies of leukocyte migration38. With further immunoflu-
orescent staining we were able to show that SCARF-1+ cups co-localised with filamentous actin and ICAM-1, 
which are known to be highly expressed in these docking structures (Fig. 5c,d).
Figure 4. Recombinant human (rh)SCARF-1 mediates the adherence of CD4+ T lymphocytes in the presence 
of rhVCAM-1, under conditions of flow. (a) A schematic representation of the immobilised protein flow 
assay. (b and c) Quantification of CD4+ and CD8+ T cells adhered to immobilised rhVCAM-1 (10 µg/ml) and 
VCAM-1 in the presence of rhSCARF-1 (10 µg/ml). (d and e) Quantification of CD4+ and CD8+ T cells  
adhered to immobilised rhVCAM-1 and rhSCARF-1 pre-treated with isotype matched control (IMC; 10 µg/ml)  
or SCARF-1 blocking antibody (10 µg/ml). ** and ****indicate statistical significance where p ≤ 0.01 and 
p ≤ 0.001, respectively. n = 3 independent experiments with different lymphocyte donors, with 12 fields of view 
taken from each.
www.nature.com/scientificreports/
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We next studied the role of SCARF-1 in the adherence of isolated CD4+ T lymphocytes to primary HSEC 
in flow-based adhesion assays. Adhesion of lymphocytes to unstimulated HSEC in vitro is very low but can be 
increased by stimulation with cytokines to induce expression of ICAM-1 and VCAM-1. In order to mimic the 
pro-inflammatory microenvironment of chronic liver disease as well as gut-derived factors, we used TNFα and 
LPS to stimulate HSEC before using antibody blockade to investigate the contribution of SCARF-1 to the adhe-
sion process. Under stimulation with TNFα alone, SCARF-1 blockade had a small inhibitory effect (17%) on 
CD4+ T cell adherence to the HSEC, which was approximately half the inhibition seen with an anti-VCAM-1 
antibody alone (37%) (Fig. 6a). Combined blockade with both antibodies on the HSEC monolayer had a synergis-
tic effect on inhibition of CD4+ T cell adhesion (64%) (Fig. 6a). We confirmed that this phenomenon was CD4+ 
T cell-specific by repeating the flow-based experiments on TNFα-stimulated HSEC with CD8+ T cells where 
SCARF-1 blockade had no effect (Supplementary Figure 6). In HSEC stimulated with LPS, SCARF-1 blockade 
on CD4+ T cell adhesion was more pronounced (31%) and was comparable to that seen with VCAM-1 blockade 
(36%) (Fig. 6b); nevertheless, the cumulative effect of dual blockade was reduced (49%) (Fig. 6b). Combined 
HSEC stimulation with TNFα and LPS again showed an effect of SCARF-1 blockade that was comparable to that 
seen with VCAM-1 alone (24% vs 26%) (Fig. 6c); however, the additive effect of dual blockade was markedly 
decreased (34%). To confirm the specificity of antibody blockade for SCARF-1 our flow-based adhesion assays 
were repeated using HSEC which had undergone siRNA-induced knockdown of SCARF-1 expression (confirmed 
knockdown in three independent isolates) which resulted in a 45% reduction in CD4+ T cell adherence (Fig. 7).
Discussion
Chronic liver disease (CLD) is an increasing global problem and a major cause of morbidity and mortality 
through the development of fibrosis and cirrhosis which can lead to liver failure or malignancies, such as hepato-
cellular carcinoma (HCC). Liver injury and fibrosis is driven by uncontrolled immune activation and persistent 
inflammation, but the factors that regulate this remain poorly understood. The hepatic sinusoidal endothelium 
is the major route for the recruitment of leukocytes from the blood and plays a major role in regulating liver 
Figure 5. SCARF-1 forms an adhesive cup for CD4+ T cell adherence to HSEC. (a–d) Representative image 
of CD4+ T cells (blue; Cell Trace Violet (CTV)-labelled) attached to TNFα-stimulated HSEC (green; Cell 
Tracker Green (CTG)-labelled) via SCARF-1 (red) adhesive cups, which are rich in (c) filamentous (F-)actin 
(pink) and (d) ICAM-1 (grey). (a) White arrows highlight adherent CD4+ T lymphocytes. Scale bar = 40 µm. 
(b) White dotted line represents the periphery of the HSEC and the white dashed line delineates the site of the 
Z stack. Scale bars = 12 µm (left) and 2 µm (right). (c) White arrow highlights adherent CD4+ T lymphocyte. 
Scale bars = 22.5 µm (top left) and 7 µm (right). (d) White arrows highlight adherent CD4+ T lymphocytes. Scale 
bars = 50 µm (top left) and 5 µm (right). (c and d) White asterisks indicate adherent CD4+ T lymphocyte in 
adhesive cup.
www.nature.com/scientificreports/
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inflammation through the ability to selectively recruit and activate lymphocyte subsets39–41. There is increased 
interest in the role of gut-derived factors, such as LPS, in regulating liver inflammation and how this interaction 
of bacterial products with the liver immunity can be targeted for therapeutic benefit2,42,43. Here we demonstrate 
a direct relationship between an LPS-regulated scavenger receptor, SCARF-1, and lymphocyte recruitment. We 
report for the first time expression of SCARF-1 in human liver tissue and a soluble form in human serum before 
going on to demonstrate a functional role for SCARF-1 in CD4+ T cell adhesion to HSEC. SCARF-1 was strongly 
expressed on hepatic sinusoids and vessels, primary sites of lymphocyte recruitment during inflammatory liver 
Figure 6. Antibody blockade of SCARF-1 on HSEC inhibits the adherence of CD4+ T lymphocytes in the 
presence of TNFα and LPS. (a,b and c; left panels) Representative images of CD4+ T cells adhered to HSEC 
stimulated with (a) TNFα (10 ng/ml), (b) LPS (1 µg/ml) or (c) TNFα and LPS together. HSEC were pre-treated 
with isotype matched controls (IMC; 10 µg/ml), SCARF-1 blocking antibody (10 µg/ml), VCAM-1 blocking 
antibody (10 µg/ml) or SCARF-1 and VCAM-1 in combination (both 10 µg/ml). Black arrowheads highlight 
adherent CD4+ T lymphocytes on the HSEC monolayer. (a,b and c; right panels) Quantification of adherent 
CD4+ T cells in the presence of the blocking antibodies, with the percentage inhibition indicated. *, **, *** and 
**** all indicate statistical significance where p ≤ 0.05, p ≤ 0.01, p ≤ 0.005 and p ≤ 0.001, respectively. ns = not 
significant. n = 3 independent experiments with different lymphocyte and HSEC donors, with 12 fields of view 
taken from each.
www.nature.com/scientificreports/
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diseases and a 60 kDa form of the protein was present in chronic liver disease samples, but absent from normal 
pathological control tissue. SCARF-1 was also present in the sinusoids of hepatocellular carcinoma (HCC) tissue 
and was observed in tumour-associated and capsule-associated vessels, all of which are important sites for lym-
phocyte trafficking in HCC.
SCARF-1 expression in HSEC was regulated in vitro by proinflammatory cytokines and bacterial LPS; impor-
tant drivers of chronic liver inflammation. Furthermore, we present evidence that TNFα- and LPS-stimulated 
up-regulation of SCARF-1 in HSEC leads to a direct interaction with CD4+ T lymphocytes. SCARF-1 has pre-
viously been shown to play a role in cell-cell adhesion in transfected cell lines34, and is able to act as a chaperone 
molecule in Hsp-mediated antigen cross presentation to both CD4+ 24 and CD8+ 44 T lymphocytes by antigen 
presenting cells (APCs); however, to our knowledge this is the first description of SCARF-1 directly contributing 
to leukocyte recruitment. Taken together, our data suggests that SCARF-1 plays a role in lymphocyte recruitment 
to hepatic sinusoidal endothelium during inflammatory and bacterial-driven injury of the liver.
Although SCARF-1 expression within the liver was predominantly associated with the sinusoidal and vascular 
endothelia (Figs 1a and 2a), we also detected SCARF-1 on stromal cells in fibrotic septa in vivo and on stellate cells 
and activated myofibroblasts in vitro (Figs 1 and 2a,b). Microbial products that activate TLRs, in particular LPS, 
can activate hepatic myofibroblasts to produce proinflammatory cytokines and extracellular matrix proteins35,45, 
thus suggesting a potential role for SCARF-1 in fibrogenesis. Furthermore, macrophages play a key role in liver 
immunology and disease, but we only found SCARF-1 expression on a small subset of liver-resident macrophages 
in vivo (Fig. 2a); consequently, given its more ubiquitous nature and elevated mRNA levels, we concentrated on 
the expression and function of HSEC-associated SCARF-1. The regulation of SCARF-1 in endothelial cells has 
only been previously studied at the transcriptional level in HUVEC where proinflammatory cytokines, such as 
TNFα, IFNγ and IL-1β, were able to inhibit SCARF-1 gene promoter activity46. This was highly suggestive of 
a possible negative feedback loop to limit inflammatory signaling during cytokine stimulation47. However, by 
studying protein expression, we now show that SCARF-1 regulation is potentially more complex. We found that 
SCARF-1 in liver tissue and primary cultured liver endothelial cells exists in different isoforms. In chronically 
inflamed liver tissue we found a specific increase in the expression of the 60 kDa form, whereas in isolated HSEC 
we detected monomeric and dimeric forms of the protein the levels of which were modulated following stimu-
lation with proinflammatory cytokines, LPS or growth factors. Further studies with a NEMO inhibitor demon-
strated that SCARF-1 expression in HSEC was not directly related to NF-κB signalling (data not shown), and 
Figure 7. siRNA knockdown of SCARF-1 in HSEC significantly decreases CD4+ T cell adherence.  
(a) Representative Western blot analysis of SCARF-1 ~180 kDa and ~90 kDa species in HSEC treated with control 
and SCARF-1 siRNA knockdown. Results are regions cropped from the same membrane (see Supplementary 
Figure 7) (b) Quantification of SCARF-1 expression in HSEC treated with siRNA knockdown of SCARF-1 
expressed as a % of expression in control HSEC. n = 3 independent experiments with different HSEC. *Indicates 
statistical significance where p ≤ 0.05. (c) Quantification of adherence of lymphocytes to monolayers of HSEC in 
flow assays pre-treated with control siRNA and SCARF-1 siRNA. n = 3 independent experiments with different 
HSEC donors, with 12 fields of view taken from each. ****Indicates statistical significance where p ≤ 0.001.
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further studies are required to determine the precise mechanism controlling expression of SCARF-1, as well as 
the functional role of the soluble form of SCARF-1.
A number of scavenger receptors, such as lectin-like oxidized LDL receptor (LOX)-148,49, stabilin-115,16,50 and 
stabilin-217, have previously been shown to mediate leukocyte adhesion to endothelial cells. This, added to the 
fact that SCARF-1 and stabilin-1 both contain a number of EGF-like moieties in their extracellular domains, 
led us to hypothesise that SCARF-1 could support lymphocyte adhesion to HSEC and thus regulate lymphocyte 
recruitment to the liver. In flow-based adhesion assay immobilized recombinant SCARF-1 on its own was unable 
to mediate lymphocyte adhesion. However, when it was co-immobilised with VCAM-1, SCARF-1 augmented 
the adhesion of Jurkat cells (Supplementary Figure 5a) and primary CD4+ T cells under flow conditions (Fig. 4b), 
whereas it had no effect on CD8+ T cells (Fig. 4c), making it one of the few lymphocyte subset-specific adhesion 
receptors. VCAM-1 has been shown to play an important role in initiating rolling of lymphocytes during recruit-
ment and therefore VCAM-1 is likely to be a pre-requisite for the initial capture of CD4+ T cells prior to firm 
adhesion by SCARF-1. The physiological relevance of our findings was suggested by the subsequent experiments 
showing that it also mediates CD4+ T cell-specific adhesion to primary HSEC under flow particularly to HSEC 
that had been stimulated with LPS, and TNFα and LPS together. Under these conditions, SCARF-1 showed adhe-
sive properties comparable to the classical adhesion molecule, VCAM-1, and combined blockade of VCAM-1 
and SCARF-1 showed an additional reduction of adhesion, thus suggesting that these two receptors could play a 
combinatorial role in CD4+ T cell binding to HSEC (Fig. 6). The identity of the receptor for SCARF-1 present on 
lymphocytes is unknown, and further studies are required to identify the ligand. We were unable to detect mRNA 
for SCARF-1 in CD4+ T cells, potentially ruling out a homotypic interaction between adjacent SCARF-1 mole-
cules, and we were also unable to detect an effect of SCARF-1 on β1 integrin activation by flow cytometry which 
suggests that SCARF-1 does not augment binding of T-cells through enhanced integrin/VCAM-1 interactions 
(data not shown). The fact that SCARF-1 was present in structures surrounding adherent CD4+ T cells suggests 
it may be involved in the organisation of cell membrane structures that promote interactions with CD4+ T cells 
potentially bringing in to play other adhesion receptors or chemokines. Confocal microscopy demonstrated that 
SCARF-1 co-localised in actin-rich endothelial cups, which also express ICAM-1 (Fig. 5c,d). Subset specificity 
is unusual in endothelial adhesion receptors, although we have reported such a role for stabilin-1 in CD4+ T cell 
adhesion15, and VAP-1 and VCAM-1 have been reported to recruit Th1 and Th2 subsets selectively in vivo51.
Our functional assays, together with our findings of constitutive expression of SCARF-1 within normal liver 
tissue and its up-regulation in HSEC by inflammatory mediators, suggests that SCARF-1 could mediate T cell 
recruitment during the early inflammatory phase of chronic liver disease pathophysiology. We propose that pro-
gressive liver injury promotes the expression of a wide range of proteases, resulting in the cleavage and release 
of a 60 kDa soluble form of SCARF-1 from the cell surface which then accumulates within chronically diseased 
tissues. The fact that SCARF-1 is down-regulated in liver cancers, particularly those that are poorly differentiated 
and thus have the worst prognosis, also suggests it may play a role in tumour immune control through recruit-
ment of inflammatory cells in response to microenvironmental signals. Taken together, its high levels of expres-
sion in the liver and the selectivity of its action suggest that SCARF-1 may be an attractive therapeutic target to 
selectively inhibit liver inflammation without disrupting systemic immune surveillance. SCARF-1 could also 
represent a new player in the gut-liver axis by regulating CD4+ T cell recruitment to liver tissue in response to 
gut-derived antigens. Several chronic liver diseases are associated with increased gut permeability and bacterial 
translocation52 and, with the onset of these conditions, SCARF-1 may play an important role in the recruitment of 
inflammatory mediators under these conditions. Further in vivo studies are required to confirm the subset spec-
ificity and consequences of SCARF-1 blockade, but our results suggest that SCARF-1 could be a new therapeutic 
target for prevention of these inflammatory conditions.
Methods
Human tissue. Human tissue and blood samples were collected from patients admitted to the University 
Hospitals Birmingham NHS Foundation Trust, with written informed consent and local ethics committee 
approval; all experiments were performed in accordance with the regulations and guidelines sanctioned by 
the West Midlands – South Birmingham Research Ethics Committee, Birmingham, UK (LREC reference 06/
Q2702/61 and 04/Q2708/41). Normal liver tissue was taken from rejected organ donors deemed unsuitable for 
transplantation or from resection margins and diseased liver tissue was obtained from patients undergoing trans-
plantation for chronic liver disease or liver malignancies.
Immunohistochemistry. Immunohistochemistry was performed on 7 μm thick acetone-fixed cryosec-
tions. Prior to staining, sections were thawed to room temperature (RT) and hydrated in PBS/0.1% Tween® 20 
(PBST) for 5 min. Endogenous peroxidase activity was then blocked with 0.3% hydrogen peroxide in methanol 
and blocking of non-specific binding was performed by incubation with Casein Solution (Vector Laboratories, 
Inc.) in 2.5% horse serum (provided with the anti-mouse or anti-rabbit ImmPRESS™ HRP (Peroxidase) sec-
ondary antibody kits; Vector Laboratories Inc.). Sections were incubated with anti-SCARF-1 (8 μg/ml; Abcam; 
ab92308) or anti-SCARF-2 (1.3 μg/ml; Sigma HPA035079) primary antibody diluted in PBS for 1 h at RT and then 
washed twice in PBST for 5 min. Isotype matched controls at appropriate concentrations were performed in all 
experiments. Subsequently, sections were incubated with the anti-mouse (SCARF-1) or anti-rabbit (SCARF-2) 
ImmPRESS™ HRP for 30 min at RT. Excess secondary antibody was washed off with PBST (twice) and sections 
were then incubated with DAB (Vector Laboratories Inc.) chromogen for 2 min, after which the reaction was 
stopped with distilled H2O. Nuclei were counterstained with Mayer’s Hematoxylin (Pioneer Research Chemicals 
Ltd.) for 30 s and washed in warm H2O for 2 min. Sections were subsequently dehydrated in sequential washes 
of alcohol3x and xylene3x and mounted using DPX (Phthalate-free) mounting medium (CellPath). Images were 
taken using an Axioskop 40 microscope (ZEISS) and surface area coverage was calculated using ImageJ software.
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Quantitative real-time PCR. Total RNA was isolated and purified from human liver tissue using the 
RNeasy® Mini Kit (Qiagen), in conjunction with the RNase-Free DNase Set (Qiagen) and to the manufacturer’s 
instructions. Approximately 20–30 mg samples of liver tissue were weighed out and then homogenised using 
gentleMACS™ M tubes (Miltenyi Biotec) and a gentleMACS™ Dissociator (Miltenyi Biotec). Alternatively, HSEC 
were cultured to confluence in 6-well culture plates (Corning CoStar), stimulated for 24 h (see ‘HSEC stimula-
tion’ below), then cells were lysed in situ by the addition of RLT buffer. RNA was subsequently isolated using the 
RNeasy® Micro Kit (Qiagen). Once isolated, RNA quantity and purity was determined using a Nanophotometer™ 
(Implen GmbH) and reverse transcription of mRNA was performed by the SuperScript®III Reverse Transcriptase 
(Thermo Fisher Scientific). mRNA expression levels of target proteins were assessed by quantitative real-time 
PCR (qPCR), using predesigned TaqMan® Gene Expression Assays (Applied Biosystems®) (Supplementary 
Table 1) and TaqMan® Universal PCR Master Mix (Applied Biosystems®). qPCR was performed on a Roche 
Lightcycler 480 (Roche) using the following program: 95 °C for 10 min and 45 cycles of 95 °C for 10 s, 60 °C for 
1 min, 72 °C for 1 s. Target mRNA levels were normalised to the housekeeping gene and a fold change of relative 
expression from the appropriate unstimulated control was calculated with the 2−ΔCt and 2−ΔΔCt methods53.
Western blot. Using gentleMACS™ M-tubes (Miltenyi Biotec), ~75 mg of frozen liver tissues were homog-
enised in CelLytic MT lysis buffer (Sigma-Aldrich) with 1% Protease Inhibitor Cocktail (Sigma-Aldrich), 1% 
Phosphatase Inhibitor Cocktail 3 (Sigma-Aldrich) and 5 U/ml DNase-I (Sigma-Aldrich). Alternatively, HSEC 
were cultured to confluence in 6-well culture plates (Corning CoStar), stimulated for 24 h (see ‘HSEC stimu-
lation’ below), then cells were lysed in situ by the lysis buffer described above. Lysate protein concentrations 
were determined against a BSA protein standard (Sigma-Aldrich) using the bicinchoninic acid (BCA) assay 
(Sigma-Aldrich) and following standard protocols. Lysates were normalised to 2 mg/ml and stored at −20 °C.
20 μg of protein lysate was resolved on a 10% SDS-PAGE and subsequently transferred to nitrocellulose 
membrane (Thermo Fisher Scientific). Membranes were blocked with 5% non-fat milk solution (Marvel) in TBS 
(SCARF-1) or PBS (SCARF-2) with 0.02% Tween20 (Sigma-Aldrich; TBS/T or PBS/T) for 1 h at room tempera-
ture followed by overnight incubation at 4 °C with the primary antibody (SCARF-1, Abcam ab92308, 6 μg/ml or 
SCARF-2, Sigma HPA035079, 0.8 µg/ml). Following this, membranes were washed 3x in PBS/T and incubated 
with a horseradish peroxidase (HRP)-conjugated ant-rabbit IgG antibody (Sigma-Aldrich, A0545, 1/ 2500) for 1 h 
at room temperature. Proteins bands were detected with Enhanced Chemiluminescent Substrate (ECL; Pierce™). 
Membranes were then stripped with Restore™ Western Stripping Buffer (Thermo Scientific) for 10 mins, washed 
in PBS/T twice and re-blocked with 5% non-fat milk in PBS/T for 1 h at room temperature and incubated over-
night at 4 °C with the housekeeping anti-β-actin antibody (Sigma-Aldrich A5441; 1/2500). Membranes were 
then washed 3x in PBS/T and incubated with HRP-conjugated ant-mouse IgG antibody (Sigma-Aldrich, A4416, 
1/2500) for 1 h at room temperature. Proteins bands were again detected via ECL.
Sandwich ELISA. Levels of soluble SCARF-1 (sSCARF-1) in healthy donor and diseased human serum were 
measured via sandwich ELISA using a commercially available kit (Biorbyt) and following the manufacturer’s 
instructions.
Immunofluorescence. For immunofluorescent staining, 7 μm acetone-fixed cryosections were thawed and 
then blocked for non-specific binding by incubation in PBS with 10% goat serum and casein solution, for 30 min at 
RT. This was followed by 1 h incubation with primary antibodies against the following antigens: SCARF-1 (8 μg/ml, 
Abcam ab92308); CD31 (5 μg/ml, DAKO JC70A); αSMA (5 μg/ml, Sigma-Aldrich IA4); CD90 (1 μg/ml, eBio-
science SE10); CK18 (1 μg/ml, DAKO DC10); EpCAM (5 μg/ml, Progen HEA125). Samples were washed three 
times in PBS followed by 30 min incubation with Alexa Fluor® conjugated secondary antibodies (1:250; Thermo 
Fisher Scientific). Nuclei were stained with 300 nM DAPI (Invitrogen) and slides were subsequently mounted 
with Fluorescence Mounting Medium (DAKO). Fluorescence images were acquired using a Zeiss 780 Zen confo-
cal fluorescence microscope (ZEISS).
Primary cell isolation and culture. Hepatic sinusoidal endothelial cells (HSEC) were isolated from ∼30 g 
human liver tissue as described previously54. Briefly, tissue was subjected to collagenase digestion (10 mg/ml 
collagenase IA; Sigma-Aldrich) and was placed on a 33%/77% Percoll (GE Healthcare) density gradient and cen-
trifuged at 800 x g for 25 min. The non-parenchymal cell layer was then removed, and the endothelial cells were 
isolated by positive immunomagnetic selection using CD31 antibody-conjugated Dynabeads (Invitrogen). The 
endothelial cells were then seeded in rat tail collagen (1 in 100; Sigma-Aldrich)-coated culture vessels in medium 
composed of human endothelial serum-free media (SFM; Invitrogen) supplemented with 10% human serum 
(HD Supplies), 10 ng/ml vascular endothelial growth factor (VEGF; PeproTech), and 10 ng/ml hepatocyte growth 
factor (HGF; PeproTech). Subsequent to the positive selection of HSEC, the residual cells were considered to be 
a mixed population of activated liver myofibroblasts (aLMFs)55 and were cultured in Dulbecco’s Modified Eagle 
medium (DMEM; Gibco™ by Thermo Fisher Scientific) with 16% FCS. Quiescent hepatic stellate cells (HSCs) 
were isolated from non-fibrotic liver tissue, as described previously55,56. Viability of HSCs was confirmed using 
trypan blue exclusion, and autofluorescence suggested a purity of >90%. HSCs were cultured in DMEM contain-
ing 16% FCS (Gibco™ by Thermo Fisher Scientific) and used within 4 passages. All cell types were grown and 
maintained at 37 °C in a humidified incubator with 5% CO2.
Human umbilical vein endothelial cells (HUVEC) were isolated via a standard protocol54 and were cultured 
on rat-tail collagen coated plastic in human endothelial SFM supplemented with 10% human serum, 10 ng/ml 
epidermal growth factor (EGF; PeproTech) and 10 µg/ml hydrocortisone (Sigma-Aldrich).
HSEC stimulation. Prior to stimulation, HSEC were incubated with endothelial SFM with 10% FCS for 
24 h. HSEC were then stimulated with either proinflammatory cytokines (tumour necrosis factor (TNF)α and 
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recombinant human interferon (IFN)γ; 10 ng/ml; both from PeproTech), lipopolysaccharide (LPS) from E. coli 
0111:B4 (1 µg/ml; Sigma-Aldrich) or tumourigenic growth factors (VEGF and HGF; 10 ng/ml) for 24 h.
Immunocytochemistry. For immunofluorescent staining of SCARF-1 in HSEC, cells were cultured to 
confluence on rat tail collagen (RTC)-coated 8-well glass bottom µ-slides (Ibidi®), subsequently stimulated (see 
‘HSEC stimulation’) and fixed in 4% paraformaldehyde (PFA). Alternatively, HSEC were cultured overnight in 
RTC-coated μ-Slides VI 0.4 (Ibidi®), stimulated for a further 24 h with 10 ng/ml TNFα and had 1 × 106 cells/ml 
CD4+ T lymphocytes perfused over them as described below (see ‘Flow adhesion assays’). HSEC and adherent 
CD4+ T cells were then fixed in 4% PFA. Following fixation, all cells were washed in PBS, permeabilised with PBS 
with 0.3% Tween® 20 for 5 min and then blocked in PBS with 10% goat serum for 20 min. The cells were then 
incubated at room temperature with anti-SCARF-1 (12 μg/ml; Abcam; ab92308) and anti-ICAM-1 (10 μg/ml; R 
& D; BBA3) primary antibodies, Alexa Fluor™ 633 Phalloidin (1 in 40; Invitrogen) or IMC antibodies diluted 
in PBS for 1 h. The cells were then washed with PBS three times and incubated with appropriate Alexa Fluor® 
conjugated secondary antibodies (1:250; Thermo Fisher Scientific). Nuclei were labeled with 300 nM DAPI. Cells 
were washed with PBS three times and left in PBS after final wash before imaging on a Zeiss 780 Zen confocal 
fluorescence microscope (ZEISS).
Cell-based ELISA. HSEC were grown to confluence in collagen-coated 96-well flat-bottom plates and media 
was changed to SFM with 10% FCS for 24 h prior to stimulation. Cells were left under basal conditions (Control) 
or stimulated for 24 h (see ‘HSEC stimulation’). Subsequently, cells were fixed in ice cold methanol for 10 mins and 
washed with PBS twice. Fixed cells were then blocked with 2% goat serum (Sigma-Aldrich) in PBS for 1 h, fol-
lowed by incubation with primary antibody (5 μg/ml; Abcam ab92308) or IMC control (5 μg/ml; Abcam ab27478) 
for 45 min at room temperature. The cells were then washed with PBS 1% bovine serum albumin (BSA; Gibco™ 
by Thermo Fisher Scientific) and incubated with a peroxidase-conjugated goat anti-rabbit secondary Ab (1/500; 
DAKO P0448) for 45 min at room temperature. The ELISA was developed using O-phenylenediamine substrate 
(OPD; DAKO) according to the manufacturer’s instructions. SCARF-1 in stimulated HSEC was calculated as the 
mean absorbance from three replicate wells minus the absorbance of an isotype-matched control antibody and 
expressed as fold change from control (unstimulated) cells.
Primary lymphocyte isolation. Peripheral blood mononuclear cells (PBMCs) were isolated from whole 
blood as previously described54. Briefly, whole blood was layered onto Lympholyte®-H (Cedarlane) and centri-
fuged at 800 x g for 25 min. The PBMC layer was removed and washed once in PBS with 2% FCS and 1 mM EDTA 
(Gibco™ by Thermo Fisher Scientific) and centrifuged at 800 x g for 5 min. A platelet depletion step was then 
performed by a second wash in PBS with 2% FCS and 1 mM EDTA and centrifugation at 350 x g for 10 min. CD4+ 
and CD8+ T lymphocytes were isolated from PBMCs by negative selection by the Dynabeads® Untouched™ 
Human CD4 T Cells Kit and Dynabeads® Untouched™ Human CD8 T Cells Kit, respectively, and in accordance 
with manufacturer’s instructions.
siRNA knockdown of SCARF-1 in HSEC. Cells were transiently transfected with 25 nM SCARF1 
Silencer® Select siRNA (s16344; Thermo Fisher Scientific) or a non-targeting siRNA control (Silencer® Select 
Negative Control No. 1 siRNA; Thermo Fisher Scientific), utilising the Lipofectamine RNAiMAX Transfection 
Reagent (Invitrogen). Briefly, 2.5 × 105 or 7.5 × 104 HSEC were seeded in rat tail collagen-coated 6-well cell 
culture plates or 0.4 Channel μ-Slides VI (Ibidi®), respectively, and cultured overnight. Subsequently, siRNA 
duplexes diluted in Opti-MEM (Gibco™ by Life Technologies) were mixed with a final concentration of 0.3% 
Lipofectamine® RNAiMAX and incubated for 10 min at room temperature. Cells were then washed twice with 
PBS and the duplex/Lipofectamine RNAiMAX mixture was added to the cells and incubated for 4 h at 37 °C. 
The duplex/Lipofectamine® RNAiMAX mixture was then removed and HSEC medium without antibiotics was 
added to the cells which were then maintained in standard culture conditions. After 24 h, transfected cells were 
stimulated with 10 ng/ml TNF-α and incubated for a further 24 h. HSEC cultured in 6-well culture plates were 
harvested in CelLytic MT lysis buffer with 1% Protease Inhibitor, 1% Phosphatase Inhibitor Cocktail 3 and 5 U/ml 
DNase-I and SCARF-1 knockdown was confirmed via Western blot analysis (see ‘Western blot’ above). HSEC 
cultured in 0.4 Channel μ-Slides VI were subsequently used in flow-based adhesion assays (see ‘Flow-based adhe-
sion assays’ below).
Flow adhesion assays. We used a modified protocol of a flow-based, recombinant protein adhesion assay, 
previously described by our lab57, to determine whether or not SCARF-1 was able to directly interact with pri-
mary lymphocytes. Briefly, μ-Slides VI 0.4 (Ibidi®) were washed twice with sterile PBS and then incubated with 
10 µg/ml recombinant human (rh)VCAM-1 (R & D Systems) and 10 µg/ml recombinant Protein G (Thermo 
Fisher Scientific) in PBS for 1 h at 37 °C. The slide was again washed twice with PBS and then incubated with 
10 µg/ml rhSCARF-1 (R & D Systems) in PBS or PBS alone (VCAM-1 control wells) for 1 h at 37 °C. Slides were 
washed in PBS twice and blocked with PBS with 10% FCS for 30 min. Finally, antibodies diluted in PBS with 0.1% 
BSA were added to the slides for 30 min prior to the flow assay. 1 × 106 cells/ml CD4+ or CD8+ T lymphocytes, 
in a flow medium of RPMI with 0.1% BSA, were then perfused over the HSEC at a physiological shear of 0.05 Pa. 
Each channel of the microslide was perfused for 5 min with T lymphocytes, before a 5 min of wash with flow 
media alone, during which video recordings were taken.
Additionally, flow adhesion assays over monolayers of HSEC, which have also previously been described by 
our lab15,58, were used to investigate the role of SCARF-1 in lymphocyte adhesion to the sinusoidal endothelium, 
under conditions of physiological flow. Briefly, approx. 7.5 × 105 HSEC were grown to confluence overnight in 
rat tail collagen-coated μ-Slides VI 0.4. Cells were then stimulated with 10 ng/ml TNFα, 1 µg/ml of LPS or both 
in combination for 24 h to promote up-regulation of classical adhesion receptors and SCARF-1. 1 × 106 cells/ml 
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CD4+ or CD8+ T lymphocytes, in a flow medium of Endothelial SFM with 0.1% BSA, were then perfused over the 
HSEC at a physiological shear of 0.05 Pa. Each channel of the microslide was perfused for 5 min with T lympho-
cytes, before a 5 min of wash with flow media alone, during which video recordings were taken.
All flow assays were imaged by phase-contrast microscopy with an Olympus IX50 Inverted Microscope 
(Olympus), with video recordings of 12 frames from each channel taken. Analysis was then performed for 
quantification of the number of adherent T lymphocytes. The number of adherent cells was then normalised 
to cells/mm2/106 cells perfused using the following equation: (adherent cells/(flow rate (0.28 ml/min)) × bolus 
(5 min) × field of view area (0.154 mm2)) × (1/concentration of lymphocytes (1 × 106 cells/ml)). The addition of 
blocking antibodies or isotype matched negative control antibodies was performed immediately preceding each 
assay and incubated for 30 min.
Statistical analyses. All data were tested for normal distribution by the D’Agostino-Pearson omnibus test. 
All parametric data are expressed as mean ± standard error of the mean (SEM) and all non-parametric data 
are expressed as median ± interquartile range (IQR), with the number of experimental repeats (n) specified in 
each case. For single comparisons, statistical significance was determined by unpaired t-test (parametric) or 
Mann-Whitney U-test (non-parametric), whereas evaluation of multiple treatments was performed by ANOVA 
with a post- hoc Tukey’s test (parametric) or Kruskall-Wallis one-way analysis of variance with post hoc Dunn’s 
test (non-parametric). A p-value of ≤0.05 was considered as statistically significant. All statistical analyses were 
undertaken using Prism® 6 software (GraphPad Software Inc.).
Data availability. The datasets generated during during the current study are available from the corresponding 
author on reasonable request.
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